Table 2 Model validation based on clinical and external data
Survival curves | 12 months | 36 months | 60 months |
|---|---|---|---|
PFS2 | |||
 Modeled Vd | 71.2% | 21.9% | 6.3% |
 Observed Vd | 68.6% | 21.7% | 8.2% |
 Modeled DVd | 84.7% | 51.3% | 32.5% |
 Observed DVd | 83.4% | 50.7% | 37.1% |
 Modeled PVd | 74.3% | 46.1% | - |
 Observed PVd | 71.4% | 45.3% | - |
 Modeled Kd | 81.3% | 47.2% | - |
 Observed Kd | 83.2% | 48.3% | - |
 Modeled IsaKd | 85.1% | 56.8% | - |
 Observed IsaKd | 86.1% | 57.7% | - |
OS | |||
 Modeled Vd | 83.30% | 51.80% | 30.10% |
 Modeled DVd | 88.00% | 63.10% | 44.00% |
 Modeled SVd | 85.70% | 57.50% | 37.40% |
 Modeled PVd | 83.60% | 52.50% | 32.20% |
 Modeled Kd | 86.50% | 59.40% | 40.00% |
 Modeled Rd | 85.50% | 58.90% | 39.30% |
 Modeled ERd | 88.00% | 64.80% | 46.50% |
 Modeled DRd | 89.20% | 67.90% | 50.60% |
 Modeled KRd | 88.30% | 65.80% | 47.90% |
 Modeled IxaRd | 86.30% | 60.80% | 41.60% |
 Modeled Kd | 83.40% | 58.00% | 40.40% |
 Modeled DKd | 86.70% | 65.20% | 49.10% |
 Modeled IsaKd | 86.80% | 65.40% | 49.30% |
 External OS with one prior lines | 90.20% | 66.30% | 49.20% |
 External OS with two prior lines | 82.10% | 58.10% | 40.80% |